WHO validates Bharat Biotech's coronavirus vaccine, Covaxin

4 November 2021
who_flag_big

The coronavirus vaccine developed by Bharat Biotech, Covaxin, has been approved by the World Health Organization (WHO) under its emergency use listing (EUL) process.

The vaccine has thus far only been approved in a handful of countries, including Iran, Mexico, Greece and Nepal.

The decision from the WHO means that travelers vaccinated with Covaxin will be able to enter the USA, under new rules due to come into force on November 8.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology